황반변성 치료제 시장 : 지역별(북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카) - 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2032년)

The Macular Degeneration Treatment Market report by Persistence Market Research offers a comprehensive analysis of market dynamics, growth factors, challenges, and emerging trends from the period 2024 to 2032. It provides insights into the current state and future outlook of the Macular Degeneration Treatment Market.

The global macular degeneration treatment market is projected to grow at a compound annual growth rate (CAGR) of 7.4% from USD 10 billion in 2024 to USD 18.8 billion by 2032.

Key Insights:

• Estimated Market Size (2024): USD 10 Billion
• Projected Market Size (2032): USD 18.8 Billion
• Global Market Growth Rate (CAGR 2024 to 2032): 7.4%

Macular Degeneration Treatment Market - Report Scope:

Macular degeneration is a chronic eye disorder affecting the central vision and is a leading cause of vision loss among older adults. The report outlines key drivers behind the demand for macular degeneration treatment, including the aging population, lifestyle changes, and advancements in diagnostic and therapeutic technologies.

Market Growth Drivers:

The market's growth is propelled by several factors. Firstly, the increasing prevalence of age-related macular degeneration (AMD) worldwide, driven by factors such as aging population, sedentary lifestyles, smoking, and genetic predisposition, fuels demand for macular degeneration treatment options such as anti-vascular endothelial growth factor (anti-VEGF) drugs, photodynamic therapy (PDT), and retinal implants. Additionally, advancements in diagnostic imaging techniques such as optical coherence tomography (OCT) and fundus autofluorescence (FAF) enable early detection, accurate diagnosis, and personalized treatment planning for patients with AMD, enhancing treatment outcomes and vision preservation. Moreover, research and development initiatives focusing on novel drug delivery systems, gene therapies, and regenerative medicine approaches offer promising avenues for innovative treatments targeting various subtypes of macular degeneration, including wet AMD, dry AMD, and geographic atrophy.

Market Restraints:

Despite the positive outlook, the Macular Degeneration Treatment Market faces certain challenges. Factors such as high treatment costs, limited insurance coverage, and reimbursement constraints may impact patient access to macular degeneration treatments, particularly in emerging markets and underserved populations, influencing market dynamics and adoption rates. Moreover, safety concerns, adverse effects, and treatment complications associated with invasive procedures such as intravitreal injections and laser photocoagulation may deter patient compliance and acceptance of macular degeneration therapies, posing challenges to market growth and penetration. Additionally, regulatory hurdles, clinical trial requirements, and intellectual property issues may delay market entry and product commercialization for novel macular degeneration treatments, hampering innovation and investment in the industry.

Market Opportunities:

The Macular Degeneration Treatment Market offers significant opportunities for innovation and market expansion. Healthcare providers and pharmaceutical companies can focus on developing next-generation therapies targeting novel pathways, molecular targets, and disease mechanisms implicated in macular degeneration pathogenesis. For instance, emerging treatment modalities such as gene editing, stem cell therapy, and neuroprotective agents hold promise for disease modification, vision restoration, and long-term management of macular degeneration. Moreover, strategic partnerships, collaborations, and technology transfer agreements facilitate knowledge exchange, resource sharing, and capacity building in the macular degeneration research and development ecosystem, accelerating the pace of innovation and translation of scientific discoveries into clinical applications. Furthermore, investments in patient education, advocacy initiatives, and community outreach programs raise awareness, reduce stigma, and improve access to macular degeneration diagnosis, treatment, and support services, empowering patients to make informed decisions and actively participate in their eye care journey.

Key Questions Addressed in the Report:

• What is the Expected CAGR of the Macular Degeneration Treatment Market from 2024 to 2032?
• What are the Key Factors Driving the Growth of the Macular Degeneration Treatment Market?
• Which Treatment Modality Holds the Largest Market Share in the Macular Degeneration Treatment Market?
• Who are the Key Players in the Global Macular Degeneration Treatment Market?
• What Strategies are Adopted by Leading Companies to Stay Competitive in the Macular Degeneration Treatment Market?

Competitive Landscape and Business Strategies:

Key players in the Macular Degeneration Treatment Market include Novartis AG, Roche Holding AG, Regeneron Pharmaceuticals, Inc., Bayer AG, and Allergan plc, among others. These companies focus on product differentiation, market expansion, and strategic collaborations to maintain a competitive edge in the market. For instance, Novartis AG offers Lucentis(R) (ranibizumab) and Beovu(R) (brolucizumab) for the treatment of wet AMD, while Roche Holding AG markets Lucentis(R) in collaboration with Novartis. Market players also invest in patient support programs, disease awareness campaigns, and digital health solutions to enhance patient engagement, adherence, and retention in macular degeneration treatment pathways.

Key Companies Profiled:

• Novartis AG
• Roche Holding AG
• Regeneron Pharmaceuticals, Inc.
• Bayer AG
• Allergan plc

Macular Degeneration Treatment Market Segmentation:

By Drug:

• Anti-vascular Endothelial Growth Factors
• Others

By Indication:

• Dry Age-related Macular Degeneration
• Wet Age-related Macular Degeneration

By Route of Administration:

• Intravenous Route
• Intravitreal Route
• Others

By Distribution Channel:

• Hospitals
• Ophthalmology Clinics
• Ambulatory Surgical Centers
• Others

By Region:

• North America
• Latin America
• Europe Macular
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Product Development and Innovation Trends

4. Key Success Factors

• 4.1. Product Adoption / Usage Analysis
• 4.2. Recent Product Launches and Approvals
• 4.3. Strategic Promotional Strategies
• 4.4. Disease Epidemiology
• 4.5. Regulatory and Reimbursement Scenario
• 4.6. Product Pipeline Assessment
• 4.7. Porters Analysis
• 4.8. PESTLE Analysis

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Outlook
  • 5.1.3. Per Capita Healthcare Expenditure Outlook
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Alternative Treatment Market Growth
  • 5.2.2. Technological Advances
  • 5.2.3. Development of Novel Products
  • 5.2.4. Regulatory Imposition
  • 5.2.5. Product Pipeline
  • 5.2.6. Per Patient Spending
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis - Impact Assessment

• 6.1. COVID-19 and Impact Analysis
  • 6.1.1. Revenue By Drug
  • 6.1.2. Revenue By Route of Administration
  • 6.1.3. Revenue By Indication
  • 6.1.4. Revenue By End User
  • 6.1.5. Revenue By Country
• 6.2. 2023 Market Scenario

7. Global Macular Degeneration Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2032

• 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Macular Degeneration Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Drug

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Mn) Analysis By Drug, 2019-2023
• 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug, 2024-2032
  • 8.3.1. Anti-vascular Endothelial Growth Factor
  • 8.3.2. Other
• 8.4. Market Attractiveness Analysis By Drug

9. Global Macular Degeneration Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Route of Administration

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2019-2023
• 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2024-2032
  • 9.3.1. Intravenous Route
  • 9.3.2. Intravitreal Route
  • 9.3.3. Others
• 9.4. Market Attractiveness Analysis By Route of Administration

10. Global Macular Degeneration Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Indication

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Mn) Analysis By Indication, 2019-2023
• 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2024-2032
  • 10.3.1. Dry Age-related Macular Degeneration
  • 10.3.2. Wet Age-related Macular Degeneration
• 10.4. Market Attractiveness Analysis By Indication

11. Global Macular Degeneration Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By End User

• 11.1. Introduction / Key Findings
• 11.2. Historical Market Size (US$ Mn) Analysis By End User, 2019-2023
• 11.3. Current and Future Market Size (US$ Mn) and Forecast By End User, 2024-2032
  • 11.3.1. Hospitals
  • 11.3.2. Ophthalmology Clinics
  • 11.3.3. Ambulatory Surgical Centers
  • 11.3.4. Others
• 11.4. Market Attractiveness Analysis By End User

12. Global Macular Degeneration Treatment Market Analysis 2019-2023 and Forecast 2024-2032, by Region

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
• 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2032
  • 12.3.1. North America
  • 12.3.2. Latin America
  • 12.3.3. Europe
  • 12.3.4. East Asia
  • 12.3.5. South Asia
  • 12.3.6. Oceania
  • 12.3.7. The Middle East and Africa (MEA)
• 12.4. Market Attractiveness Analysis By Region

13. North America Macular Degeneration Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 13.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2032
  • 13.3.1. By Country
    • 13.3.1.1. U.S.
    • 13.3.1.2. Canada
  • 13.3.2. By Drug
  • 13.3.3. By Route of Administration
  • 13.3.4. By Indication
  • 13.3.5. By End User
• 13.4. Market Attractiveness Analysis
  • 13.4.1. By Country
  • 13.4.2. By Drug
  • 13.4.3. By Route of Administration
  • 13.4.4. By Indication
  • 13.4.5. By End User
• 13.5. Market Trends
• 13.6. Key Market Participants - Intensity Mapping
• 13.7. Drivers and Restraints - Impact Analysis
• 13.8. Country Level Analysis & Forecast
  • 13.8.1. U.S. Macular Degeneration Treatment Market Analysis
    • 13.8.1.1. Introduction
    • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.1.2.1. By Drug
      • 13.8.1.2.2. By Route of Administration
      • 13.8.1.2.3. By Indication
      • 13.8.1.2.4. By End User
  • 13.8.2. Canada Macular Degeneration Treatment Market Analysis
    • 13.8.2.1. Introduction
    • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.2.2.1. By Drug
      • 13.8.2.2.2. By Route of Administration
      • 13.8.2.2.3. By Indication
      • 13.8.2.2.4. By End User

14. Latin America Macular Degeneration Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2032
  • 14.3.1. By Country
    • 14.3.1.1. Brazil
    • 14.3.1.2. Mexico
    • 14.3.1.3. Argentina
    • 14.3.1.4. Rest of Latin America
  • 14.3.2. By Drug
  • 14.3.3. By Route of Administration
  • 14.3.4. By Indication
  • 14.3.5. By End User
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Drug
  • 14.4.3. By Route of Administration
  • 14.4.4. By Indication
  • 14.4.5. By End User
• 14.5. Market Trends
• 14.6. Key Market Participants - Intensity Mapping
• 14.7. Drivers and Restraints - Impact Analysis
• 14.8. Country Level Analysis & Forecast
  • 14.8.1. Brazil Macular Degeneration Treatment Market Analysis
    • 14.8.1.1. Introduction
    • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.1.2.1. By Drug
      • 14.8.1.2.2. By Route of Administration
      • 14.8.1.2.3. By Indication
      • 14.8.1.2.4. By End User
  • 14.8.2. Mexico Macular Degeneration Treatment Market Analysis
    • 14.8.2.1. Introduction
    • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.2.2.1. By Drug
      • 14.8.2.2.2. By Route of Administration
      • 14.8.2.2.3. By Indication
      • 14.8.2.2.4. By End User
  • 14.8.3. Argentina Macular Degeneration Treatment Market Analysis
    • 14.8.3.1. Introduction
    • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.3.2.1. By Drug
      • 14.8.3.2.2. By Route of Administration
      • 14.8.3.2.3. By Indication
      • 14.8.3.2.4. By End User

15. Europe Macular Degeneration Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2032
  • 15.3.1. By Country
    • 15.3.1.1. Germany
    • 15.3.1.2. Italy
    • 15.3.1.3. France
    • 15.3.1.4. U.K.
    • 15.3.1.5. Spain
    • 15.3.1.6. BENELUX
    • 15.3.1.7. Russia
    • 15.3.1.8. Rest of Europe
  • 15.3.2. By Drug
  • 15.3.3. By Route of Administration
  • 15.3.4. By Indication
  • 15.3.5. By End User
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By Drug
  • 15.4.3. By Route of Administration
  • 15.4.4. By Indication
  • 15.4.5. By End User
• 15.5. Market Trends
• 15.6. Key Market Participants - Intensity Mapping
• 15.7. Drivers and Restraints - Impact Analysis
• 15.8. Country Level Analysis & Forecast
  • 15.8.1. Germany Macular Degeneration Treatment Market Analysis
    • 15.8.1.1. Introduction
    • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.1.2.1. By Drug
      • 15.8.1.2.2. By Route of Administration
      • 15.8.1.2.3. By Indication
      • 15.8.1.2.4. By End User
  • 15.8.2. Italy Macular Degeneration Treatment Market Analysis
    • 15.8.2.1. Introduction
    • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.2.2.1. By Drug
      • 15.8.2.2.2. By Route of Administration
      • 15.8.2.2.3. By Indication
      • 15.8.2.2.4. By End User
  • 15.8.3. France Macular Degeneration Treatment Market Analysis
    • 15.8.3.1. Introduction
    • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.3.2.1. By Drug
      • 15.8.3.2.2. By Route of Administration
      • 15.8.3.2.3. By Indication
      • 15.8.3.2.4. By End User
  • 15.8.4. U.K. Macular Degeneration Treatment Market Analysis
    • 15.8.4.1. Introduction
    • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.4.2.1. By Drug
      • 15.8.4.2.2. By Route of Administration
      • 15.8.4.2.3. By Indication
      • 15.8.4.2.4. By End User
  • 15.8.5. Spain Macular Degeneration Treatment Market Analysis
    • 15.8.5.1. Introduction
    • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.5.2.1. By Drug
      • 15.8.5.2.2. By Route of Administration
      • 15.8.5.2.3. By Indication
      • 15.8.5.2.4. By End User
  • 15.8.6. BENELUX Macular Degeneration Treatment Market Analysis
    • 15.8.6.1. Introduction
    • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.6.2.1. By Drug
      • 15.8.6.2.2. By Route of Administration
      • 15.8.6.2.3. By Indication
      • 15.8.6.2.4. By End User
  • 15.8.7. Russia Macular Degeneration Treatment Market Analysis
    • 15.8.7.1. Introduction
    • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.7.2.1. By Drug
      • 15.8.7.2.2. By Route of Administration
      • 15.8.7.2.3. By Indication
      • 15.8.7.2.4. By End User

16. South Asia Macular Degeneration Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2032
  • 16.3.1. By Country
    • 16.3.1.1. India
    • 16.3.1.2. Indonesia
    • 16.3.1.3. Malaysia
    • 16.3.1.4. Thailand
    • 16.3.1.5. Rest of South Asia
  • 16.3.2. By Drug
  • 16.3.3. By Route of Administration
  • 16.3.4. By Indication
  • 16.3.5. By End User
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Drug
  • 16.4.3. By Route of Administration
  • 16.4.4. By Indication
  • 16.4.5. By End User
• 16.5. Market Trends
• 16.6. Key Market Participants - Intensity Mapping
• 16.7. Drivers and Restraints - Impact Analysis
• 16.8. Country Level Analysis & Forecast
  • 16.8.1. India Macular Degeneration Treatment Market Analysis
    • 16.8.1.1. Introduction
    • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.1.2.1. By Drug
      • 16.8.1.2.2. By Route of Administration
      • 16.8.1.2.3. By Indication
      • 16.8.1.2.4. By End User
  • 16.8.2. Indonesia Macular Degeneration Treatment Market Analysis
    • 16.8.2.1. Introduction
    • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.2.2.1. By Drug
      • 16.8.2.2.2. By Route of Administration
      • 16.8.2.2.3. By Indication
      • 16.8.2.2.4. By End User
  • 16.8.3. Malaysia Macular Degeneration Treatment Market Analysis
    • 16.8.3.1. Introduction
    • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.3.2.1. By Drug
      • 16.8.3.2.2. By Route of Administration
      • 16.8.3.2.3. By Indication
      • 16.8.3.2.4. By End User
  • 16.8.4. Thailand Macular Degeneration Treatment Market Analysis
    • 16.8.4.1. Introduction
    • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.4.2.1. By Drug
      • 16.8.4.2.2. By Route of Administration
      • 16.8.4.2.3. By Indication
      • 16.8.4.2.4. By End User

17. East Asia Macular Degeneration Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2032
  • 17.3.1. By Country
    • 17.3.1.1. China
    • 17.3.1.2. Japan
    • 17.3.1.3. South Korea
  • 17.3.2. By Drug
  • 17.3.3. By Route of Administration
  • 17.3.4. By Indication
  • 17.3.5. By End User
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Drug
  • 17.4.3. By Route of Administration
  • 17.4.4. By Indication
  • 17.4.5. By End User
• 17.5. Market Trends
• 17.6. Key Market Participants - Intensity Mapping
• 17.7. Drivers and Restraints - Impact Analysis
• 17.8. Country Level Analysis & Forecast
  • 17.8.1. China Macular Degeneration Treatment Market Analysis
    • 17.8.1.1. Introduction
    • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.1.2.1. By Drug
      • 17.8.1.2.2. By Route of Administration
      • 17.8.1.2.3. By Indication
      • 17.8.1.2.4. By End User
  • 17.8.2. Japan Macular Degeneration Treatment Market Analysis
    • 17.8.2.1. Introduction
    • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.2.2.1. By Drug
      • 17.8.2.2.2. By Route of Administration
      • 17.8.2.2.3. By Indication
      • 17.8.2.2.4. By End User
  • 17.8.3. South Korea Macular Degeneration Treatment Market Analysis
    • 17.8.3.1. Introduction
    • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.3.2.1. By Drug
      • 17.8.3.2.2. By Route of Administration
      • 17.8.3.2.3. By Indication
      • 17.8.3.2.4. By End User

18. Oceania Macular Degeneration Treatment Market 2019-2023 and Forecast 2024-2032

• 18.1. Introduction
• 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 18.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2032
  • 18.3.1. By Country
    • 18.3.1.1. Australia
    • 18.3.1.2. New Zealand
  • 18.3.2. By Drug
  • 18.3.3. By Route of Administration
  • 18.3.4. By Indication
  • 18.3.5. By End User
• 18.4. Market Attractiveness Analysis
  • 18.4.1. By Country
  • 18.4.2. By Drug
  • 18.4.3. By Route of Administration
  • 18.4.4. By Indication
  • 18.4.5. By End User
• 18.5. Market Trends
• 18.6. Key Market Participants - Intensity Mapping
• 18.7. Drivers and Restraints - Impact Analysis
• 18.8. Country Level Analysis & Forecast
  • 18.8.1. Australia Macular Degeneration Treatment Market Analysis
    • 18.8.1.1. Introduction
    • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.1.2.1. By Drug
      • 18.8.1.2.2. By Route of Administration
      • 18.8.1.2.3. By Indication
      • 18.8.1.2.4. By End User
  • 18.8.2. New Zealand Macular Degeneration Treatment Market Analysis
    • 18.8.2.1. Introduction
    • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.2.2.1. By Drug
      • 18.8.2.2.2. By Route of Administration
      • 18.8.2.2.3. By Indication
      • 18.8.2.2.4. By End User

19. Middle East and Africa (MEA) Macular Degeneration Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 19.1. Introduction
• 19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 19.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2032
  • 19.3.1. By Country
    • 19.3.1.1. Turkey
    • 19.3.1.2. GCC Countries
    • 19.3.1.3. South Africa
    • 19.3.1.4. North Africa
    • 19.3.1.5. Rest of Middle East and Africa
  • 19.3.2. By Drug
  • 19.3.3. By Route of Administration
  • 19.3.4. By Indication
  • 19.3.5. By End User
• 19.4. Market Attractiveness Analysis
  • 19.4.1. By Country
  • 19.4.2. By Drug
  • 19.4.3. By Route of Administration
  • 19.4.4. By Indication
  • 19.4.5. By End User
• 19.5. Market Trends
• 19.6. Key Market Participants - Intensity Mapping
• 19.7. Drivers and Restraints - Impact Analysis
• 19.8. Country Level Analysis & Forecast
  • 19.8.1. Turkey Macular Degeneration Treatment Market Analysis
    • 19.8.1.1. Introduction
    • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.1.2.1. By Drug
      • 19.8.1.2.2. By Route of Administration
      • 19.8.1.2.3. By Indication
      • 19.8.1.2.4. By End User
  • 19.8.2. GCC Countries Macular Degeneration Treatment Market Analysis
    • 19.8.2.1. Introduction
    • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.2.2.1. By Drug
      • 19.8.2.2.2. By Route of Administration
      • 19.8.2.2.3. By Indication
      • 19.8.2.2.4. By End User
  • 19.8.3. South Africa Macular Degeneration Treatment Market Analysis
    • 19.8.3.1. Introduction
    • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.3.2.1. By Drug
      • 19.8.3.2.2. By Route of Administration
      • 19.8.3.2.3. By Indication
      • 19.8.3.2.4. By End User
  • 19.8.4. North Africa Macular Degeneration Treatment Market Analysis
    • 19.8.4.1. Introduction
    • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.4.2.1. By Drug
      • 19.8.4.2.2. By Route of Administration
      • 19.8.4.2.3. By Indication
      • 19.8.4.2.4. By End User

20. Market Structure Analysis

• 20.1. Market Analysis by Tier of Companies
• 20.2. Market Share Analysis (%) of Top Players
• 20.3. Market Presence Analysis
  • 20.3.1. By Regional footprint of Players
  • 20.3.2. Product footprint by Players
  • 20.3.3. Channel Foot Print by Players

21. Competition Analysis

• 21.1. Competition Dashboard
• 21.2. Competition Benchmarking
• 21.3. Competition Deep Dive (Tentative List)
  • 21.3.1. F. Hoffmann-La Roche Ltd.
    • 21.3.1.1. Overview
    • 21.3.1.2. Product Portfolio
    • 21.3.1.3. Key Financials
    • 21.3.1.4. Sales Footprint
    • 21.3.1.5. SWOT Analysis
    • 21.3.1.6. Strategy Overview
  • 21.3.2. Novartis AG
    • 21.3.2.1. Overview
    • 21.3.2.2. Product Portfolio
    • 21.3.2.3. Key Financials
    • 21.3.2.4. Sales Footprint
    • 21.3.2.5. SWOT Analysis
    • 21.3.2.6. Strategy Overview
  • 21.3.3. Bayer AG
    • 21.3.3.1. Overview
    • 21.3.3.2. Product Portfolio
    • 21.3.3.3. Key Financials
    • 21.3.3.4. Sales Footprint
    • 21.3.3.5. SWOT Analysis
    • 21.3.3.6. Strategy Overview
  • 21.3.4. Pfizer Inc.
    • 21.3.4.1. Overview
    • 21.3.4.2. Product Portfolio
    • 21.3.4.3. Key Financials
    • 21.3.4.4. Sales Footprint
    • 21.3.4.5. SWOT Analysis
    • 21.3.4.6. Strategy Overview
  • 21.3.5. Bausch Health Companies Inc.
    • 21.3.5.1. Overview
    • 21.3.5.2. Product Portfolio
    • 21.3.5.3. Key Financials
    • 21.3.5.4. Sales Footprint
    • 21.3.5.5. SWOT Analysis
    • 21.3.5.6. Strategy Overview
  • 21.3.6. Regeneron Pharmaceuticals Inc.
    • 21.3.6.1. Overview
    • 21.3.6.2. Product Portfolio
    • 21.3.6.3. Key Financials
    • 21.3.6.4. Sales Footprint
    • 21.3.6.5. SWOT Analysis
    • 21.3.6.6. Strategy Overview
  • 21.3.7. Amgen Inc.
    • 21.3.7.1. Overview
    • 21.3.7.2. Product Portfolio
    • 21.3.7.3. Key Financials
    • 21.3.7.4. Sales Footprint
    • 21.3.7.5. SWOT Analysis
    • 21.3.7.6. Strategy Overview
  • 21.3.8. Biogen
    • 21.3.8.1. Overview
    • 21.3.8.2. Product Portfolio
    • 21.3.8.3. Key Financials
    • 21.3.8.4. Sales Footprint
    • 21.3.8.5. SWOT Analysis
    • 21.3.8.6. Strategy Overview
  • 21.3.9. Samsung Bioepis
    • 21.3.9.1. Overview
    • 21.3.9.2. Product Portfolio
    • 21.3.9.3. Key Financials
    • 21.3.9.4. Sales Footprint
    • 21.3.9.5. SWOT Analysis
    • 21.3.9.6. Strategy Overview
  • 21.3.10. Santen Pharmaceutical Co., Ltd.
    • 21.3.10.1. Overview
    • 21.3.10.2. Product Portfolio
    • 21.3.10.3. Key Financials
    • 21.3.10.4. Sales Footprint
    • 21.3.10.5. SWOT Analysis
    • 21.3.10.6. Strategy Overview

22. Assumptions and Acronyms Used

23. Research Methodology